46 completed, 3 recruiting, 3 unknown, 2 active not recruiting. 54 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 54 | Completed 46, Recruiting 3, Unknown 3, Active not recruiting 2 |
| Phase 2 | 4 | Completed 3, Unknown 1 |
Follow Meningitis, Meningococcal: new trials by email Literature Review of Meningitis, Meningococcal trials Research Report on Meningitis, Meningococcal
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 3-5 Months experimental vaccine, Active Comparator vaccine - Epidemic Meningitis, Meningococcal Vaccines | Phase 3 | Recruiting | Sinovac Biotech Co., Ltd | 880 | 2026-03-25 | 2026-08-10 |
| Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 12-23 Months experimental vaccine, Active Comparator vaccine - Epidemic Meningitis, Meningococcal Vaccines | Phase 3 | Recruiting | Sinovac Biotech Co., Ltd | 1040 | 2026-03-22 | 2026-08-10 |
| Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 6-11 Months experimental vaccine, Active Comparator vaccine - Epidemic Meningitis, Meningococcal Vaccines | Phase 3 | Recruiting | Sinovac Biotech Co., Ltd | 1040 | 2026-03-22 | 2026-08-10 |
| Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 2-6 Years experimental vaccine, active comparator vaccine - Epidemic Meningitis, Meningococcal Vaccines | Phase 3 | Active not recruiting | Sinovac Biotech Co., Ltd | 660 | 2026-03-22 | 2026-08-10 |
| A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 7 to 17 Year Olds MCV4, MPSV4 - Meningococcal Meningitis | Phase 3 | Completed | CanSino Biologics Inc. | 840 | 2024-12-14 | 2026-08-06 |
| A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years batch 1 of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) (MCV4), batch 2 of MCV4, batch 3 of MCV4 - Meningococcal Meningitis | Phase 3 | Completed | CanSino Biologics Inc. | 1480 | 2024-03-20 | 2026-08-06 |
| A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 18-59 Year Olds MCV4, MPSV4 - Meningococcal Meningitis | Phase 3 | Active not recruiting | CanSino Biologics Inc. | 840 | 2024-03-01 | 2025-07-29 |
| A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in a 4 to 6 Year-old Population MCV4, MSPV4 - Epidemic Meningitis | Phase 3 | Completed | CanSino Biologics Inc. | 1000 | 2023-09-16 | 2025-07-03 |
| Immunogenicity and Safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Volunteers Aged From 3 to 5 Months Meningococcal ACYW135 Polysaccharide Conjugate Vaccine, Meningococcal A and C Polysaccharide Conjugate Vaccine - Meningitis, Meningococcal | Phase 3 | Unknown | Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd | 1200 | 2021-12-18 | 2024-04-04 |
| Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine MenABCWY vaccine, Placebo, MenACWY vaccine - Meningitis, Meningococcal | Phase 3 | Completed | GlaxoSmithKline | 1250 | 2021-01-25 | 2024-07-03 |
| A Phase III Clinical Trial of the Group A and C Meningococcal Polysaccharide Vaccine Experimental Group A and C meningococcal polysaccharide vaccine, Control Group A and C meningococcal polysaccharide vaccine - Meningitis, Meningococcal | Phase 3 | Completed | Institute of Medical Biology, Chinese Academy of Medical Sciences | 1280 | 2020-09-15 | 2026-09-29 |
| A Phase III Clinical Trial of the Group A Meningococcal Polysaccharide Vaccine Experimental Group A meningococcal polysaccharide vaccine, Control Group A meningococcal polysaccharide vaccine - Meningitis, Meningococcal | Phase 3 | Unknown | Wei Cun | 1280 | 2020-09-14 | 2020-12-30 |
| Study to Assess Immunegnicity & Safety of Pentavalent Meningococcal Vaccine (NmCV-5) NmCV-5, Menactra - Meningococcal Meningitis | Phase 3 | Completed | Serum Institute of India Pvt. Ltd. | 1800 | 2019-08-20 | 2021-07-27 |
| Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe MenACYW conjugate vaccine, Meningococcal group A, C, W-135, and Y conjugate vaccine, DTaP-IPV-HB-Hib vaccine - Meningococcal Infections | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 1660 | 2018-12-14 | 2025-03-03 |
| Conjugate Vaccine Against Meningococcus C a Brazilian Project MenCC-BIO Vaccine, Combined - CRM197 - Serogroup C Meningococcal Meningitis | Phase 2 / Phase 3 | Unknown | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | 1644 | 2018-09-25 | 2018-10-10 |
| Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants Bexsero (GSK Biologicals' Meningococcal group-B vaccine/ rMenB+OMV NZ), Prevnar13, Pediarix - Infections, Meningococcal | Phase 3 | Completed | GlaxoSmithKline | 1196 | 2018-07-27 | 2026-08-20 |
| Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US MenACYW conjugate vaccine, MenACYW-135 conjugate vaccine, DTaP-IPV//Hib vaccine - Healthy Volunteers (Meningococcal Infection) | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 2627 | 2018-04-25 | 2024-10-15 |
| Immunogenicity and Safety of a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine in Children MenACYW conjugate vaccine - Meningococcal Infections | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 91 | 2018-02-27 | 2022-04-06 |
| Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Toddlers Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine, Meningococcal polysaccharide groups A, C, W-135 and Y Conjugate vaccine - Meningitis, Meningococcal Meningitis | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 918 | 2017-02-24 | 2022-04-05 |
| Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 Years Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate, Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine - Meningitis, Meningococcal Meningitis | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 1000 | 2017-02-17 | 2022-03-28 |
Showing 20 of 54. Sign in to see all of them.
Meningococcal Infections (28) · Meningitis (20) · Chickenpox (3) · Haemophilus Infections (3) · Measles (3) · Mumps (3) · Rubella (3) · Tetanus (2) · Whooping Cough (2) · Diphtheria (1) · Encephalitis, Japanese (1) · Hepatitis A (1) · Hepatitis B (1) · Papillomavirus Infections (1)
Bacterial Infections (54) · Bacterial Infections and Mycoses (54) · Central Nervous System Bacterial Infections (54) · Central Nervous System Diseases (54) · Central Nervous System Infections (54) · Gram-Negative Bacterial Infections (54) · Infections (54) · Meningitis, Bacterial (54) · Neisseriaceae Infections (54) · Nervous System Diseases (54) · Neuroinflammatory Diseases (54) · Meningitis (34) · Meningococcal Infections (26) · Virus Diseases (7) · RNA Virus Infections (6)
Meningococcal Vaccines (14) · MenACWY-CRM vaccine (4) · measles, mumps, rubella, varicella vaccine (4) · 4CMenB vaccine (3) · Chickenpox Vaccine (3) · Hepatitis A Vaccines (3) · Hepatitis B Vaccines (3) · Heptavalent Pneumococcal Conjugate Vaccine (3) · Measles-Mumps-Rubella Vaccine (3) · 13-valent pneumococcal vaccine (2) · PEDIARIX (2) · RotaTeq (2) · diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine (2) · 10-valent pneumococcal vaccine (1) · Boostrix (1)
Novartis Vaccines (18) · Sanofi Pasteur, a Sanofi Company (13) · CanSino Biologics Inc. (4) · Sinovac Biotech Co., Ltd (4) · GlaxoSmithKline (3) · Novartis (3) · Pfizer (2) · Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd (1) · Institute of Medical Biology, Chinese Academy of Medical Sciences (1) · Merck Sharp & Dohme LLC (1) · Public Health England (1) · Serum Institute of India Pvt. Ltd. (1) · The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) (1) · Wei Cun (1)
United States (16) · China (10) · Germany (8) · Spain (7) · Czechia (6) · Italy (6) · Puerto Rico (6) · Finland (5) · Argentina (3) · Australia (3) · Canada (3) · Chile (3) · Hungary (3) · Poland (3) · United Kingdom (3)
Elizabeth Miller, MD (1) · Isti Suharjanti, Dr (1) · Lin Du (1) · Qing Wang (1)
PMID 29253560, PMID 19476428, PMID 19812260, PMID 20164251, PMID 20189491, PMID 20655261, PMID 21339701, PMID 21389149, PMID 22094635, PMID 23324563, PMID 24873986, PMID 25308927, PMID 25483566, PMID 26075813, PMID 26232542, PMID 26479973, PMID 26756390, PMID 28318767, PMID 28580917, PMID 29038320, PMID 29789243, PMID 31110098, PMID 31279564, PMID 31327652, PMID 32209015, PMID 32387012, PMID 32852352, PMID 33020485, PMID 33325757, PMID 33814028, PMID 35164991, PMID 37224196, PMID 37256991, PMID 37256992, PMID 39722560, PMID 40665158, PMID 41276263, PMID 41337697
2009 (2), 2016 (2), 2017 (2), 2018 (2), 2005 (1), 2014 (1), 2019 (1)